Corporate Board Profile
Tech Score: 7/100
1 mention(s) identify STELIOS PAPADOPOULOS, PH.D. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| EXELIXIS, INC. | 2024-04-18 | Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, and was on the faculty of the Department of Cell Biology at New York University Medical Center. | Dr. Papadopoulos has a Ph.D. in Biophysics and an M.B.A. in Finance, with a background including faculty position in Cell Biology and experience as an investment banker focused on biotechnology, indicating strong technical and scientific expertise relevant to programming. |
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-30 | Having founded multiple life sciences companies and worked as an investment banker focused on the life sciences industry, Dr. Papadopoulos brings to our Board of Directors a first-hand understanding of the demands of establishing, growing and running life sciences businesses. |
| 2016-04-15 | Dr. Papadopoulos brings to our Board of Directors a first-hand understanding of the demands of establishing, growing and running life sciences businesses. He was an investment banker focusing on the biotechnology and pharmaceutical sectors. |
| 2017-04-26 | Dr. Papadopoulos brings to our Board of Directors a firsthand understanding of the demands of establishing, growing, and running life sciences businesses. |
| 2018-04-27 | Dr. Papadopoulos brings to our Board of Directors a firsthand understanding of the demands of establishing, growing and running life sciences businesses. |
| 2019-04-30 | Dr. Papadopoulos brings to our Board of Directors a first-hand understanding of the demands of establishing, growing and running life sciences businesses. |
| 2020-04-20 | Dr. Papadopoulos serves as the Chairman of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994, and Regulus Therapeutics Inc., a biopharmaceutical company. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors. |
| 2021-04-23 | Dr. Papadopoulos serves as the Chairman of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994, Regulus Therapeutics Inc., a biopharmaceutical company, and Eucrates Biomedical Acquisition Corp., a special purpose acquisition company. |
| 2022-04-29 | Dr. Papadopoulos serves as the Chairman of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-13 | Dr. Papadopoulos holds a Ph.D. in Biophysics and an M.B.A. in Finance, both from New York University. Our Board has concluded that Dr. Papadopoulos should continue to serve as a director of Exelixis as of the date of this Proxy Statement due to his training as a scientist, his knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries. |
| 2019-04-11 | Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University. |
| 2020-04-09 | Dr. Papadopoulos should continue to serve as a director of Exelixis due to his training as a scientist, his knowledge and experience with respect to the biotechnology, healthcare and pharmaceutical industries, his broad leadership experience resulting from extensive service on various boards, his knowledge and experience with respect to finance matters, and his ability to bring historic knowledge and continuity to the Board. |
| 2021-04-15 | Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University. He was a co-founder of biotechnology companies and has extensive leadership experience. |
| 2022-04-14 | Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, all from New York University. |
| 2024-04-18 | Dr. Papadopoulos holds an M.S. in Physics, a Ph.D. in Biophysics and an M.B.A. in Finance, and was on the faculty of the Department of Cell Biology at New York University Medical Center. |
Data sourced from SEC filings. Last updated: 2025-10-11